Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of ChAdOx1 LS2 and MVA LS2 Malaria Vaccines
NCT03203421Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Jul 2017
- Primary completion
- Dec 2017
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of ChAdOx1 LS2 and MVA LS2 in malaria (4 arms), sponsored by University of Oxford. Primary endpoints: Safety and tolerability of ChAdOx1 LS2 administered alone and with MVA LS2 and Efficacy of ChAdOx1 LS2 and MVA LS2 against malaria sporozoite challenge at 90 days. Started Jul 2017; status: completed.
02
Drugs
ChAdOx1 LS2MVA LS2
03
Conditions
malaria
Beyond the preview
Go deeper on NCT03203421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03203421.